Navigation Links
MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
Date:10/15/2009

GAITHERSBURG, Md., Oct. 15 /PRNewswire/ -- MedImmune today announced that researchers will present data on several inflammatory disease programs at the annual meeting of the American College of Rheumatology, from October 17 to 21, 2009 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

"Through our research into novel disease pathways involved in autoimmune disorders, we continue to fulfill our mission of using scientific excellence to deliver life-changing medicines for patients with rheumatic diseases," said Anthony Coyle, PhD., vice president, head of respiratory, inflammation, and autoimmune disease research. "Representing some of our most recent progress, we are pleased to share data relevant to the development of new therapies for conditions such as lupus, rheumatoid arthritis, and scleroderma."

The schedule for MedImmune's nine posters and two oral presentations at the meeting, starting on Saturday October 17, is as follows:

  • Relationship Between Disease Activity and Type 1 Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis (Oral Presentation)-Steven Greeberg, Ph.D., Sunday, October 18 at 3:00 p.m. in Room 202 B
  • In Vitro and In Vivo Properties of MEDI-571, a Human Anti IL-17A Antibody in Development for the Treatment of Patients with Rheumatoid Arthritis - Matthew Sleeman, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 8
  • Utilising Assay Systems Relevant to IL-6 Mechanisms in Rheumatoid Arthritis to Demonstrate Efficacy of a Novel Human Anti-IL-6 Antibody, CAT6001 -Donna Finch, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 45, Abstract: 587
  • MEDI5117: A Human High Affinity Anti-IL-6 Monoclonal Antibody with Enhanced Serum Half-Life in Development for the Treatment of Inflammation and Rheumatological Diseases - Jacques Moisan, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 401
  • Tissue Plasminogen Activator (tPA) Restores Normal Fibrinolysis / Coagulation Balance in Kidney and Reverses Clinical Score in Skin in a Murine Graft-Versus-Host Disease Model of Scleroderma: Proof of Concept for Therapeutic Fibrinolysis in Scleroderma - Timothy Burwell, B.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1062
  • Neutralization of Angiopoietin 2 Reduces Disease in Murine Arthritis and Augments Efficacy of Anti-TNF Treatment - Brian Naiman, MS., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 666
  • Critical Requirement of RAGE for Development of Lung Fibrosis in An Experimental Model of Systemic Sclerosis -Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1053
  • Depletion of Inducible Co-Stimulator (ICOS) Bearing T Cells Inhibits Expansion of T Follicular Helper Cells (TFH) and Prevents Disease in a Graft Versus Host Mouse Model of Scleroderma - Gianluca Carlesso, Ph.D., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1065
  • Autoimmune-Driven Skin Fibrosis: The Critical Requirement for IFNAR1 in An Experimental Model of Systemic Sclerosis - Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1067
  • Human S100 Proteins Differentially Regulate Pro-Inflammatory Cytokine Release and Cell Migration - Bo Chen, Ph.D., Tuesday, October 20 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1331
  • CAM-3001; a Novel Human Monoclonal Antibody against GM-CSFR-a, in Subjects with Rheumatoid Arthritis (RA): Results of a Phi Study (Oral Presentation) - Gerd-R Burmester, M.D., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1926

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
2. HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
3. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
4. MedImmune Announces Zook as President
5. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
8. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
9. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
10. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
11. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... announced the three Winners and six Finalists of the 2017 Blavatnik Regional Awards ... the Blavatnik Family Foundation and administered by the New York Academy of Sciences ...
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO ... ASTER Labs ), Inc. has been selected for membership in ARCS Alumni ...
Breaking Biology Technology:
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):